Literature DB >> 988842

Heterogeneity of immunologic markers and surface morphology in childhood lymphoblastic lymphoma.

E S Jaffe, R C Braylan, M M Frank, I Green, C W Berard.   

Abstract

The neoplastic cells from seven patients with childhood lymphoblastic lymphoma were studied for cell surface markers and surface morphology in the scanning electron microscope (SEM). The cells were studied for surface immunoglobulin (Slg), complement receptors (EAC), receptors for cytophilic antibody (IgGEA), and nonimmune rosette formation with sheep red blood cells (E). In one patient the cells exclusively bound E, suggesting a T-lymphocytic origin. In two patients the cells bound EAC, but demonstrated no other B-lymphocytic markers. In two patients no markers were detected, and in two patients receptors for both E and EAC were demonstrated. Additional studies in one of these patients permitted simultaneous demonstration of both markers on the same neoplastic cells. The neoplastic cells were also examined by SEM after fixation and critical point dehydration. No consistent surface morphology was observed. In four patients the cells were predominately smooth, whereas in two patients variable numbers of surface microvilli were present. A correlation of the surface features with membrane markers could not be established. A comparison of the surface markers with clinical and cytologic features revealed clinical homogeneity in spite of the heterogeneous immunologic markers. This heterogeneity was most likely a reflection of neoplastic alteration and disordered differentiation of the cells. The observation of complement receptors on the cells of four cases is a feature not previously reported in this disease and should be investigated in other presumed T-cell malignancies.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 988842

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

Review 2.  The T lymphoblastic malignancies.

Authors:  L M Nadler; E L Reinherz; S F Schlossman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Immunologic diagnosis and monitoring of human acute leukemias: a review.

Authors:  M Maheu; M A Baker; J A Falk; R N Taub
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

4.  Characterization of non-Hodgkin's lymphomas using multiple cell markers. Immunologic, morphologic, and cytochemical studies of 72 cases.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

5.  Human T-cell malignancies: Correlative clinical, histopathologic, immunologic, and cytochemical analysis of 23 cases.

Authors:  D M Knowles; J P Halper
Journal:  Am J Pathol       Date:  1982-02       Impact factor: 4.307

6.  Malignant lymphomas: cell surface markers and advances in classification.

Authors:  J A Strauchen
Journal:  West J Med       Date:  1981-10

7.  Terminal deoxynucleotidyl transferase (TdT) and membrane receptors in human leukemia and lymphoma -- first experience with lyophilized cells.

Authors:  O Wetter; D K Hossfeld; K H Linder; D Brandhorst
Journal:  Klin Wochenschr       Date:  1981-04-15

8.  Preliminary evidence of dual-marked lymphocytes in thoracic duct lymph fluid.

Authors:  J C Cicciarelli; Y Iwaki; P I Terasaki; K Guidera; S Shirahama; R Billing; M Hermes; L Cardman; T Kano; S Iwatsuki; L Koep; R Weil; T E Starzl
Journal:  Transplant Proc       Date:  1980-09       Impact factor: 1.066

Review 9.  Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.

Authors:  Elaine S Jaffe; Nancy Lee Harris; Harald Stein; Peter G Isaacson
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113

Review 10.  Malignant lymphomas as tumours of the immune system.

Authors:  C W Berard; J Cossman; E S Jaffe
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.